Effect of deferiprone on liver iron overload and fibrosis in hepatitis C virus-infected thalassemia

Hemoglobin

Volumn 30, Issue 2, 2006, Pages 209-214

  Chen, An Chyi ^a   Peng, Ching Tien ^a   Wu, Shu Fen ^a   Wu, Kang Hsi ^a   Chiang, I Ping ^a   Tsai, Chang Hai ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

Author keywords

Chelating agent; Deferiprone (L1); Desferrioxamine (DFO); Hepatitis C virus (HCV); Iron overload; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DEFERIPRONE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; IRON; IRON CHELATING AGENT;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER FIBROSIS; LONG TERM CARE; MALE; SCHOOL CHILD; SCORING SYSTEM; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; COMBINED MODALITY THERAPY; DRUG EVALUATION; FEMALE; FERRITINS; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; LIVER CIRRHOSIS; MALE; PYRIDONES; RETROSPECTIVE STUDIES; THALASSEMIA;

HEPATITIS C VIRUS;

EID: 33745580269     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260600642518     Document Type: Conference Paper

References (17)

1. Ian RW, George S, Amar PD, Maria G, Artonio P, Renzo GM, Rita G, Elas S, Alan RC. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent thalassemia. Blood 2002; 100(5):1566-1569.
2. Risdon RA, Barry M, Flynn DM. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassemia. J Pathol 1975; 116(2):83-95.
3. Forget BG. Thalassemia syndrome. In: Hoffman R, Benz EJ, Shathl SJ, Furie B, Cohen HJ, Silberstein LE, McGlare P, Eds. Hematology Basic Principles and Practice, 3rd ed. Philadelphia: Churchill Livingstone 2000:485-510.
4. Ardalan FA, Osquei MRF, Toosi MN, Guiti I. Synergic effect of chronic hepatitis C infection and β thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC Gastroenterol 2004; 4:17-20.
5. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, Bissoli F, Ceriani R, Ballare M, Massari M, Trischitta C, Fiore P, Orlandi A, Morini L, Mattioli M, Oldani S, Cesana B, Fiorelli G. Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 2002; 97(5):1204-1210.
6. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002; 36(5)678-691.
7. Peng CT, Chow KC, Chen JH, Chiang YP, Tsai CH. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Hematol 2003; 70(6):392-397.
8. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103(2):361-364.
9. Porter JB, Hoyes KP, Abeysinghe RD, Brooks PN, Huehns ER, Hider RC. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood 1991; 78(10):2727-2734.
10. Ferriprox® (package insert). Apotex Europe Ltd. 1999.
11. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102(1):17-23.
12. Scarle J, Kerr J, Halliday J, Powell L. Iron storage disease. In: MacSween R, Anthony P, Scheuer P, Burt A, Portmann B, Eds. Pathology of the Liver. Edinburgh: Churchill Livingstone. 1994:219-241.
13. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003:46-61.
14. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappelini MD, Verlato G. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850:227-231.
15. Nancy FO, Gray MB, Doreen M, Matitiahu B, Laurence MB, Ross GM, Robert AM, Peter PL, Douglas MT, Gideon K. Iron chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332(14):918-922.
16. Hoffbrand AV, Al Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91(1):295-300.
17. Maggio A, D'Amico G, Morabito A, Ciacio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, Giuseppe D, Ascola D, Rizzo A, Midiri M. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28(2):196-208.